Literature DB >> 26647310

The exome sequencing identified the mutation in YARS2 encoding the mitochondrial tyrosyl-tRNA synthetase as a nuclear modifier for the phenotypic manifestation of Leber's hereditary optic neuropathy-associated mitochondrial DNA mutation.

Pingping Jiang1, Xiaofen Jin2, Yanyan Peng3, Meng Wang2, Hao Liu2, Xiaoling Liu4, Zengjun Zhang4, Yanchun Ji2, Juanjuan Zhang5, Min Liang2, Fuxin Zhao4, Yan-Hong Sun6, Minglian Zhang7, Xiangtian Zhou4, Ye Chen1, Jun Qin Mo8, Taosheng Huang9, Jia Qu4, Min-Xin Guan10.   

Abstract

Leber's hereditary optic neuropathy (LHON) is the most common mitochondrial disorder. Nuclear modifier genes are proposed to modify the phenotypic expression of LHON-associated mitochondrial DNA (mtDNA) mutations. By using an exome sequencing approach, we identified a LHON susceptibility allele (c.572G>T, p.191Gly>Val) in YARS2 gene encoding mitochondrial tyrosyl-tRNA synthetase, which interacts with m.11778G>A mutation to cause visual failure. We performed functional assays by using lymphoblastoid cell lines derived from members of Chinese families (asymptomatic individuals carrying m.11778G>A mutation, or both m.11778G>A and heterozygous p.191Gly>Val mutations and symptomatic subjects harboring m.11778G>A and homozygous p.191Gly>Val mutations) and controls lacking these mutations. The 191Gly>Val mutation reduced the YARS2 protein level in the mutant cells. The aminoacylated efficiency and steady-state level of tRNA(Tyr) were markedly decreased in the cell lines derived from patients both carrying homozygous YARS2 p.191Gly>Val and m.11778G>A mutations. The failure in tRNA(Tyr) metabolism impaired mitochondrial translation, especially for polypeptides with high content of tyrosine codon such as ND4, ND5, ND6 and COX2 in cells lines carrying homozygous YARS2 p.191Gly>Val and m.11778G>A mutations. The YARS2 p.191Gly>Val mutation worsened the respiratory phenotypes associated with m.11778G>A mutation, especially reducing activities of complexes I and IV. The respiratory deficiency altered the efficiency of mitochondrial ATP synthesis and increased the production of reactive oxygen species. Thus, mutated YARS2 aggravates mitochondrial dysfunctions associated with the m.11778G>A mutation, exceeding the threshold for the expression of blindness phenotype. Our findings provided new insights into the pathophysiology of LHON that were manifested by interaction between mtDNA mutation and mutated nuclear-modifier YARS2.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26647310     DOI: 10.1093/hmg/ddv498

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  42 in total

Review 1.  Emerging mechanisms of aminoacyl-tRNA synthetase mutations in recessive and dominant human disease.

Authors:  Rebecca Meyer-Schuman; Anthony Antonellis
Journal:  Hum Mol Genet       Date:  2017-10-01       Impact factor: 6.150

2.  Biochemical Evidence for a Nuclear Modifier Allele (A10S) in TRMU (Methylaminomethyl-2-thiouridylate-methyltransferase) Related to Mitochondrial tRNA Modification in the Phenotypic Manifestation of Deafness-associated 12S rRNA Mutation.

Authors:  Feilong Meng; Xiaohui Cang; Yanyan Peng; Ronghua Li; Zhengyue Zhang; Fushan Li; Qingqing Fan; Anna S Guan; Nathan Fischel-Ghosian; Xiaoli Zhao; Min-Xin Guan
Journal:  J Biol Chem       Date:  2017-01-03       Impact factor: 5.157

3.  Complex I mutations synergize to worsen the phenotypic expression of Leber's hereditary optic neuropathy.

Authors:  Yanchun Ji; Juanjuan Zhang; Yuanyuan Lu; Qiuzi Yi; Mengquan Chen; Shipeng Xie; Xiaoting Mao; Yun Xiao; Feilong Meng; Minglian Zhang; Rulai Yang; Min-Xin Guan
Journal:  J Biol Chem       Date:  2020-07-28       Impact factor: 5.157

Review 4.  Maternally inherited mitochondrial respiratory disorders: from pathogenetic principles to therapeutic implications.

Authors:  Martine Uittenbogaard; Anne Chiaramello
Journal:  Mol Genet Metab       Date:  2020-06-27       Impact factor: 4.797

5.  Recurrent heteroplasmy for the MT-ATP6 p.Ser148Asn (m.8969G>A) mutation in patients with syndromic congenital sideroblastic anemia of variable clinical severity.

Authors:  Simon Berhe; Matthew M Heeney; Dean R Campagna; John F Thompson; Eric J White; Tristen Ross; Roy W A Peake; Jeffery D Hanrahan; Vilmarie Rodriguez; Deborah L Renaud; Mrinal S Patnaik; Eugenia Chang; Sylvia S Bottomley; Mark D Fleming
Journal:  Haematologica       Date:  2018-07-13       Impact factor: 9.941

6.  A hypertension-associated mitochondrial DNA mutation alters the tertiary interaction and function of tRNALeu(UUR).

Authors:  Mi Zhou; Meng Wang; Ling Xue; Zhi Lin; Qiufen He; Wenwen Shi; Yaru Chen; Xiaofen Jin; Haiying Li; Pingping Jiang; Min-Xin Guan
Journal:  J Biol Chem       Date:  2017-07-05       Impact factor: 5.157

7.  A hypertension-associated mitochondrial DNA mutation introduces an m1G37 modification into tRNAMet, altering its structure and function.

Authors:  Mi Zhou; Ling Xue; Yaru Chen; Haiying Li; Qiufen He; Bibin Wang; Feilong Meng; Meng Wang; Min-Xin Guan
Journal:  J Biol Chem       Date:  2017-12-08       Impact factor: 5.157

8.  Mito-Nuclear Interactions Affecting Lifespan and Neurodegeneration in a Drosophila Model of Leigh Syndrome.

Authors:  Carin A Loewen; Barry Ganetzky
Journal:  Genetics       Date:  2018-03-01       Impact factor: 4.562

9.  An innovative strategy to clone positive modifier genes of defects caused by mtDNA mutations: MRPS18C as suppressor gene of m.3946G>A mutation in MT-ND1 gene.

Authors:  María Elena Rodríguez-García; Francisco Javier Cotrina-Vinagre; Patricia Carnicero-Rodríguez; Francisco Martínez-Azorín
Journal:  Hum Genet       Date:  2017-05-19       Impact factor: 4.132

Review 10.  Disease-Associated Genetic Variation in Human Mitochondrial Protein Import.

Authors:  Emmanuelle Nicolas; Rossella Tricarico; Michelle Savage; Erica A Golemis; Michael J Hall
Journal:  Am J Hum Genet       Date:  2019-05-02       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.